IndependentPress

  In 1993, molecular biologist Cynthia Kenyon and her colleagues published a revolutionary study demonstrating that mutating a single gene in the worm C. elegans doubled its lifespan. Compared to control worms, the mutant worms appeared younger by several key metrics. The landmark study fundamentally proved that aging is not an unchangeable , random biological process but a process driven by mechanisms that can be studied, influenced, and slowed. Kenyon's research marked the beginning of the modern study of biological aging (known as geroscience). Since then, research labs and companies have sprouted around the world aiming to research and rethink what it means to grow older.   Kenyon's findings came at an important moment in history. Since the beginning of the 1900s Human lifespans have more than doubled, largely because of public health initiatives such as access to chlorinated water, vaccines, and penicillin. These initiatives helped to eradicate many of the deadly di...

  For over two decades, SpaceX has been an outlier in the aerospace industry, consistently questioning the traditional valuation models used for defense contractors. Starting from a venture-backed valuation of $12 billion in 2015, the company’s internal share price has risen significantly, driven by the successful reuse of itsFalcon 9 booster rocket. By late 2025, following the operationalization of the Starship launch system, the private market valuation had boosted to $800 billion.   The transition to a $1.77 trillion initial public offering (IPO) target price in June 2026 represents a shift from valuing SpaceX as a launch provider to valuing it as a cofounder of the space-based, AI-driven economy. Historically, aerospace firms like Boeing or Lockheed Martin have traded at lower multiples because their growth is restrained by government budgets. SpaceX, however, is being valued like a high-growth SaaS and utility company. This valuation assumes that SpaceX will not on...